Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
John D. Hayball , Gary K. Heinemann , Preethi Eldi , Manjun Li
European Journal of Medicinal Chemistry 214 113248 -113248
1
2021
Targeting CDK2 in cancer: challenges and opportunities for therapy
Solomon Tadesse , Abel T. Anshabo , Neil Portman , Elgene Lim
Drug Discovery Today 25 ( 2) 406 -413
107
2020
Assessment of type II diabetes mellitus drug therapy in diabetes clinic of a tertiary care teaching hospital in Addis Ababa
Segewkal Hawaze , AbelTesfaye Anshabo , AlemsegedAyele Asfaw , NahomMulugeta Mamo
Archives of Pharmacy Practice 5 ( 3) 113
3
2014
Intra-articular Injection of a B Cell Depletion Antibody Enhances Local Exposure to the Joint-Draining Lymph Node in Mice with Collagen-Induced Arthritis
Alina D Lam , Ian K Styles , Danielle Senyschyn , Enyuan Cao
Molecular Pharmaceutics 20 ( 4) 2053 -2066
1
2023
Intestinal Lymphatic Biology, Drug Delivery and Therapeutics: Current status and Future directions
Sanjeevini Babu Reddiar , Yining Xie , Mohammad Abdallah , Sifei Han
Pharmacological Reviews
2024
CDK9: A Comprehensive Review of Its Biology, and Its Role as a Potential Target for Anti-Cancer Agents.
Robert Milne , Hugo Albrecht , Shudong Wang , Abel Tesfaye Anshabo
Frontiers in Oncology 11 678559
32
2021
Validation of the Amharic Version of the M. D. Anderson Symptom Inventory and Assessment of Symptoms in Ethiopian Cancer Patients
Abel Tesfaye Anshabo , Sefinew Migbaru , Atalay Mulu , Dawit Negusu
Journal of Pain and Symptom Management 51 ( 5) 947 -953
9
2016
Validation of the Amharic Version of the Brief Pain Inventory for Utility in Ethiopian Cancer Patients
Abel Tesfaye Anshabo , Sefinew Migbaru , Dagmawit Awoke , Wondemagegnhu Tigeneh
Pain Practice 17 ( 8) 1023 -1031
1
2017
Validation of the Amharic Version of the Brief Fatigue Inventory for Assessment of Cancer-Related Fatigue in Ethiopian Cancer Patients.
Girma Tekle Gebremariam , Abel Tesfaye Anshabo , Wondemagegnhu Tigeneh , Ephrem Engidawork
Journal of Pain and Symptom Management 56 ( 2) 264 -272
1
2018
LS007, a potent and orally bioavailable CDK9 inhibitor, suppresses the growth of triple-negative and estrogen receptor-positive breast cancer
Muhammed Hamidur Rahaman , Yinghui Zhang , Md Saiful Islam , Gary Heinemann
Cancer Research 79 ( 13_Supplement) 4427 -4427
2019
An orally bioavailable and highly efficacious inhibitor of CDK9/FLT3 for the treatment of acute myeloid leukemia
Abel Tesfaye Anshabo , Laychiluh Bantie , Sarah Diab , Jimma Lenjisa
Cancers 14 ( 5) 1113 -1113
10
2022